Thompson Siegel & Walmsley’s Enzo Biochem, Inc. ENZ Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-6,800	Closed	-$31K	–	817
2016 Q1	$31K	Hold	6,800	–	–	﹤0.01%	486
2015 Q4	$31K	Hold	6,800	–	–	﹤0.01%	499
2015 Q3	$22K	Hold	6,800	–	–	﹤0.01%	532
2015 Q2	$21K	Hold	6,800	–	–	﹤0.01%	555
2015 Q1	$20K	Hold	6,800	–	–	﹤0.01%	567
2014 Q4	$30K	Hold	6,800	–	–	﹤0.01%	514
2014 Q3	$35K	Hold	6,800	–	–	﹤0.01%	495
2014 Q2	$36K	Hold	6,800	–	–	﹤0.01%	481
2014 Q1	$28K	Buy	+6,800	New	+$23.3K	﹤0.01%	509

Other funds holding ENZ

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Thompson Siegel & Walmsley's ENZ Position: Q2 2016 in Review

Thompson Siegel & Walmsley sold out of Enzo Biochem, Inc. (ENZ) in Q2 2016, closing a stake of 6,800 shares — an estimated $31K sold.

Thompson Siegel & Walmsley first reported a position in ENZ in Q1 2014 and held it in 9 quarters. The position peaked at $36K in Q2 2014. 104 funds tracked by Wall St. Rank hold ENZ as of Q2 2016.

Thompson Siegel & Walmsley reported no remaining Enzo Biochem, Inc. position as of Q2 2016 after selling out during the quarter.
Thompson Siegel & Walmsley sold 6,800 Enzo Biochem, Inc. shares in Q2 2016, an estimated $31K.
Thompson Siegel & Walmsley first reported a position in Enzo Biochem, Inc. in Q1 2014 and held it in 9 quarters.
Thompson Siegel & Walmsley's Enzo Biochem, Inc. position peaked at $36K in Q2 2014.
104 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2016.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2016, filed 5 Aug 2016.